MELINTA THERAPEUTICS, INC. Intellectual Property Contracts & Agreements
10 Contracts & Agreements
- License Agreements (10 contracts)
- Amendment No. 2 to Exclusive License and Development Agreement, dated as of May 8, 2013, and amended as of September 26, 2013, by and between Cempra Pharmaceuticals, inc. and... (Filed With SEC on November 7, 2018)
- License Agreement, dated September 28, 2018, between the Company and A. Menarini Industrie Farmaceutiche Riunite S.r.l (Filed With SEC on November 7, 2018)
- License and Supply Agreement, dated November 30, 2010, by and between Melinta Therapeutics, Inc. and Cydex Pharmaceuticals, Inc. (a wholly owned subsidiary of Ligand... (Filed With SEC on June 8, 2018)
- Amended and Restated License Agreement, dated May 1, 2017, between Melinta Therapeutics, Inc. and Wakunaga Pharmaceutical Co. Ltd (Filed With SEC on June 8, 2018)
- Amendment to the License Agreement, dated as of January 6, 2009, by and between Eli Lilly and Company and Targanta Therapeutics Corporation (Filed With SEC on March 14, 2018)
- Amended and Restated License Agreement, dated May 1, 2017, between Melinta Therapeutics, Inc. and Wakunaga Pharmaceutical Co. Ltd (Filed With SEC on March 14, 2018)
- Option and License Agreement (Filed With SEC on February 25, 2016)
- AMENDMENT NO. 1 TO EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENT (Filed With SEC on October 29, 2013)
- EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENT (Filed With SEC on July 31, 2013)
- Portions of this exhibit marked [*] are requested to be treated confidentially. COLLABORATIVE RESEARCH AND DEVELOPMENT AND LICENSE AGREEMENT (Filed With SEC on October 12, 2011)
